TriSalus Life Sciences Inc

Insider buying surge at TriSalus signals confidence in its immunotherapy platform—executives buy shares at the public‑offering price, hinting at strong near‑term prospects.

TriSalus insider buy: co‑founder Michael Stansky’s zero‑price stock option signals confidence in the company’s immunotherapy pipeline, yet highlights TSL’s high‑risk, high‑reward status.